Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease

Abstract

Importance of the field: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality throughout the world. Combination therapy with albuterol and ipratropium bromide was approved > 15 years ago for the treatment of COPD. We review the mechanism of action, clinical efficacy, and safety of albuterol, ipratropium and combined albuterol-ipratropium therapy.

Areas covered in this review: We conducted a PubMed literature search using the keywords COPD, albuterol, ipratropium bromide and Combivent^® (Boehringer Ingelheim Corp., Ridgefield, CT, USA); pertinent references within the identified citations are included in the review. Data from the manufacturers are also evaluated.

What the reader will gain: At the time of its approval, albuterol/ipratropium bromide was an innovative combination of existing medications for the treatment of COPD. The combined formulation provides better improvement in airflow than either component alone and, by reducing the number of separate inhalers, simplifies therapy and improves compliance compared with the individual components.

Take home message: The recent development and approval of longer acting and more potent β agonists, anticholinergics and newer combination treatments have surpassed many of the advantages of combined albuterol–ipratropium for the treatment of patients with stable COPD.

Keywords::

• albuterol
• bronchodilator
• chronic obstructive pulmonary disease
• ipratropium bromide

Acknowledgements

This manuscript has been data checked by Boehringer Ingelheim.

Notes